[go: up one dir, main page]

HK1222677A1 - 特異性嵌合抗原受體重導向性 細胞及其使用方法 - Google Patents

特異性嵌合抗原受體重導向性 細胞及其使用方法

Info

Publication number
HK1222677A1
HK1222677A1 HK16110734.2A HK16110734A HK1222677A1 HK 1222677 A1 HK1222677 A1 HK 1222677A1 HK 16110734 A HK16110734 A HK 16110734A HK 1222677 A1 HK1222677 A1 HK 1222677A1
Authority
HK
Hong Kong
Prior art keywords
antigen receptor
chimeric antigen
specific chimeric
redirecting cell
redirecting
Prior art date
Application number
HK16110734.2A
Other languages
English (en)
Inventor
Stephen Forman
Armen Mardiros
Original Assignee
Hope City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51527938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1222677(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hope City filed Critical Hope City
Publication of HK1222677A1 publication Critical patent/HK1222677A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
HK16110734.2A 2013-03-15 2016-09-09 特異性嵌合抗原受體重導向性 細胞及其使用方法 HK1222677A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/844,048 US9657105B2 (en) 2013-03-15 2013-03-15 CD123-specific chimeric antigen receptor redirected T cells and methods of their use
PCT/US2014/029109 WO2014144622A2 (en) 2013-03-15 2014-03-14 Cd123-specific chimeric antigen receptor redirected t cells and methods of their use

Publications (1)

Publication Number Publication Date
HK1222677A1 true HK1222677A1 (zh) 2017-07-07

Family

ID=51527938

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110734.2A HK1222677A1 (zh) 2013-03-15 2016-09-09 特異性嵌合抗原受體重導向性 細胞及其使用方法

Country Status (16)

Country Link
US (3) US9657105B2 (zh)
EP (2) EP2968415B1 (zh)
JP (4) JP6588004B2 (zh)
KR (4) KR102556831B1 (zh)
CN (2) CN111926028A (zh)
AU (3) AU2014228911A1 (zh)
BR (1) BR112015023701B1 (zh)
CA (1) CA2907216C (zh)
DK (1) DK2968415T3 (zh)
ES (1) ES2747099T3 (zh)
HK (1) HK1222677A1 (zh)
IL (4) IL289883B2 (zh)
MX (2) MX2015013195A (zh)
NZ (1) NZ712351A (zh)
RU (1) RU2711114C2 (zh)
WO (1) WO2014144622A2 (zh)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9629877B2 (en) 2013-05-14 2017-04-25 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (CAR) T-cells
AU2014268364A1 (en) 2013-05-24 2015-12-10 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
EP3021853A1 (en) 2013-07-18 2016-05-25 Baylor College Of Medicine Method of enhancing potency of immune cells
AU2014376328A1 (en) * 2014-01-13 2016-07-21 Christine E. BROWN Chimeric antigen receptors (CARs) having mutations in the Fc spacer region and methods for their use
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
CA2938887C (en) * 2014-02-14 2023-04-11 Laurence J. N. Cooper Chimeric antigen receptors and methods of making
WO2015140268A1 (en) * 2014-03-19 2015-09-24 Cellectis Cd123 specific chimeric antigen receptors for cancer immunotherapy
PL3888674T3 (pl) * 2014-04-07 2024-09-23 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
KR20170037625A (ko) 2014-07-21 2017-04-04 노파르티스 아게 Cll-1 키메라 항원 수용체를 사용한 암의 치료
EP3660042B1 (en) * 2014-07-31 2023-01-11 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
RU2020117196A (ru) 2014-08-19 2020-10-15 Новартис Аг Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
IL308324A (en) * 2014-09-19 2024-01-01 Hope City IL13RA2-targeted chimeric antigen receptor T cells
US20170333480A1 (en) * 2014-11-05 2017-11-23 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
WO2016116626A1 (en) 2015-01-23 2016-07-28 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
JP7264592B2 (ja) 2015-01-26 2023-04-25 ザ ユニバーシティー オブ シカゴ ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用
US20180170992A1 (en) 2015-01-26 2018-06-21 The University Of Chicago CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
BR112017013981A2 (pt) * 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
JP6858128B2 (ja) 2015-02-18 2021-04-14 エンリヴェックス セラピューティクス リミテッド 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
BR112017021308A2 (pt) * 2015-04-06 2018-09-25 Subdomain, Llc polipeptídeos contendo domínio de ligação de forma e uso dos mesmos
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
US10100118B2 (en) * 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
CN107708811B (zh) 2015-04-21 2021-04-30 恩立夫克治疗有限责任公司 治疗性汇集的血液凋亡细胞制剂与其用途
WO2016180467A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
CA2987037A1 (en) 2015-05-29 2016-12-08 Amphivena Therapeutics, Inc. Use of cd33/cd3 bispecific tandem diabodies for the treatment of acute myeloid leukemia (aml)
WO2016203048A1 (en) 2015-06-19 2016-12-22 Kobold Sebastian Pd-1-cd28 fusion proteins and their use in medicine
US10822419B2 (en) 2015-06-26 2020-11-03 University Of Southern California Masking chimeric antigen receptor T cells for tumor-specific activation
WO2017015490A1 (en) 2015-07-21 2017-01-26 City Of Hope T cells for expression of chimeric antigen receptors and other receptors
CN108026534B (zh) * 2015-08-05 2021-08-31 赛莱博迈德公司 嵌合抗原受体和其中表达有嵌合抗原受体的t细胞
EP3352784A4 (en) * 2015-09-23 2019-06-26 Cytoimmune Therapeutics, LLC FLT3-FACED CAR CELLS FOR IMMUNOTHERAPY
WO2017062628A1 (en) 2015-10-06 2017-04-13 City Of Hope Chimeric antigen receptors targeted to psca
IL300420B2 (en) 2015-10-16 2024-09-01 Univ Columbia Compositions and methods for inhibition of lineage specific antigens
US11723922B2 (en) 2015-10-16 2023-08-15 Ludwig-Maximilians-Universität München CXCR6-transduced T cells for targeted tumor therapy
MY194628A (en) * 2015-10-23 2022-12-07 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric constructs and uses thereof
US11059879B2 (en) 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
KR20180083874A (ko) * 2015-11-04 2018-07-23 사울 제이. 프라이스맨 Her2를 표적화하는 키메라 항원 수용체
US12139526B2 (en) * 2015-12-03 2024-11-12 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
US20190000880A1 (en) 2015-12-30 2019-01-03 Novartis Ag Immune effector cell therapies with enhanced efficacy
KR20180110141A (ko) 2016-02-18 2018-10-08 엔리벡스 테라퓨틱스 리미티드 암을 치료하기 위한 면역요법과 사이토카인 조절 요법의 조합
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
WO2017172981A2 (en) * 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
EP3443096B1 (en) 2016-04-15 2023-03-01 Novartis AG Compositions and methods for selective expression of chimeric antigen receptors
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
MX2018015414A (es) 2016-06-30 2019-08-01 Hoffmann La Roche Terapia de célula t adoptiva mejorada.
EP3490590A2 (en) 2016-08-01 2019-06-05 Novartis AG Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
CN107793481A (zh) * 2016-08-31 2018-03-13 南京传奇生物科技有限公司 一种靶向人cd123的嵌合受体配体及其应用
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
PL3532497T3 (pl) 2016-10-26 2024-11-04 The Board Of Trustees Of The Leland Stanford Junior University Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji
KR20240076829A (ko) * 2016-11-16 2024-05-30 아블린쓰 엔.브이. Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드
WO2018102761A1 (en) 2016-12-02 2018-06-07 City Of Hope Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors
WO2018140725A1 (en) 2017-01-26 2018-08-02 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy
CN110612119B (zh) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
KR20190135007A (ko) * 2017-03-31 2019-12-05 자임워크스 인코포레이티드 종양 항원 제시 유도체 작제물 및 그의 용도
KR20190142775A (ko) 2017-04-19 2019-12-27 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 조작된 항원 수용체를 발현하는 면역 세포
CA3059753A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
TWI832818B (zh) * 2017-07-07 2024-02-21 南韓商韓美藥品股份有限公司 新穎的治療性酵素融合蛋白及其用途
KR20200055037A (ko) 2017-09-19 2020-05-20 메사추세츠 인스티튜트 오브 테크놀로지 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
AR123115A1 (es) 2017-10-18 2022-11-02 Novartis Ag Composiciones y métodos para la degradación selectiva de proteínas
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
EP3700926A1 (en) * 2017-10-25 2020-09-02 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3707165A4 (en) * 2017-11-07 2021-09-08 The Board of Regents of The University of Texas System TARGETING LILRB4 WITH CAR-T OR CAR-NK CELLS IN CANCER TREATMENT
WO2019099433A2 (en) 2017-11-14 2019-05-23 Arcellx, Inc. D-domain containing polypeptides and uses thereof
BR112020008939A2 (pt) 2017-11-14 2020-10-20 Arcellx, Inc. terapias de células imunes multifuncionais
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
CA3083118A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
GB201719646D0 (en) * 2017-11-27 2018-01-10 Bivictrix Therapeutics Ltd Therapy
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
CN108276495B (zh) * 2018-01-24 2022-03-18 博生吉医药科技(苏州)有限公司 靶向csf1r嵌合抗原受体修饰的nk92mi细胞和t细胞及其制法和应用
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
SG11202008796VA (en) 2018-03-14 2020-10-29 The United States Of America As Represented By The Secretary Anti-cd33 chimeric antigen receptors and their uses
WO2019195583A1 (en) * 2018-04-06 2019-10-10 Mustang Bio, Inc. Manufacturing methods for cell-based therapeutic compositions
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
SG11202011830SA (en) 2018-06-13 2020-12-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
EP3817767A1 (en) * 2018-07-02 2021-05-12 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
CA3105816A1 (en) * 2018-07-10 2020-01-16 Precigen, Inc. Ror-1 specific chimeric antigen receptors and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP7557882B2 (ja) 2018-09-28 2024-09-30 マサチューセッツ インスティテュート オブ テクノロジー コラーゲンに局在化される免疫調節分子およびその方法
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research Methods and materials for treating cancer
US20200222462A1 (en) * 2018-11-30 2020-07-16 Mustang Bio, Inc. Methods of treatment using decitabine and a cd123-targeted therapy
BR112021011874A2 (pt) 2018-12-20 2021-09-08 Novartis Ag Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
CN113329792B (zh) 2019-02-15 2024-06-28 诺华股份有限公司 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113748202B (zh) 2019-03-01 2024-07-16 艾欧凡斯生物治疗公司 由液体肿瘤扩增肿瘤浸润淋巴细胞及其治疗用途
AU2020237633A1 (en) 2019-03-08 2021-08-05 Klinikum Der Universität München CCR8 expressing lymphocytes for targeted tumor therapy
US20220145252A1 (en) 2019-03-29 2022-05-12 City Of Hope Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
EP3769816A1 (en) * 2019-07-25 2021-01-27 Ospedale Pediatrico Bambino Gesù Car-cd123 vector and uses thereof
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
CN110904048A (zh) * 2019-12-04 2020-03-24 合肥中科干细胞再生医学有限公司 一种car-cd123t2嵌合抗原受体t细胞及其应用
WO2021127024A1 (en) * 2019-12-16 2021-06-24 Washington University Chimeric antigen receptor dendritic cells (car-dcs) and methods of making and using same
CA3165274A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
US20230149460A1 (en) 2020-03-10 2023-05-18 Massachusetts Institute Of Technology Methods for generating engineered memory-like nk cells and compositions thereof
CA3173981A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of npm1c-positive cancer
CN113493772B (zh) * 2020-04-08 2022-10-18 华中农业大学 可分泌性表达免疫毒素的嵌合抗原受体修饰的免疫细胞
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
KR20230024967A (ko) 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN112079927B (zh) * 2020-09-18 2021-12-28 西安桑尼赛尔生物医药有限公司 一种cd123结合蛋白、含其的car及其应用
CN112521505B (zh) * 2020-12-11 2022-07-29 华道(上海)生物医药有限公司 抗cd123抗体及其应用
CN112646033B (zh) * 2020-12-16 2022-04-12 北京艺妙神州医药科技有限公司 靶向cd123的嵌合抗原受体及其用途
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2023021113A1 (en) 2021-08-18 2023-02-23 Julius-Maximilians-Universität Würzburg Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
EP4460519A1 (en) 2022-01-05 2024-11-13 Gyala Therapeutics Sociedad Limitada Anti-cd84 antibodies and chimeric antigen receptors
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024094004A1 (zh) * 2022-11-03 2024-05-10 重庆精准生物技术有限公司 靶向cd123的全人源抗体及其应用
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024123835A1 (en) 2022-12-06 2024-06-13 Dynamic Cell Therapies, Inc. Engineered switches for immune cell activity and methods of use thereof
WO2024123836A1 (en) 2022-12-06 2024-06-13 Dynamic Cell Therapies, Inc. Immune-activating complexes
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
CN117430721B (zh) * 2023-10-25 2024-06-25 北京景达生物科技有限公司 Cd123靶向car-nk细胞的制备及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102264A1 (en) 2000-10-18 2002-08-01 Cheung Nai-Kong V. Uses of monoclonal antibody 8H9
US8414892B2 (en) 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
EP1718310A4 (en) 2004-02-06 2009-05-06 Elan Pharm Inc METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
WO2008127735A1 (en) 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
KR101666229B1 (ko) 2008-02-08 2016-10-14 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
HRP20211788T1 (hr) 2008-08-26 2022-02-18 City Of Hope Postupak i pripravci za poboljšanje anti-tumorskog efektorskog funkcioniranja t stanica
US20120100140A1 (en) 2009-01-23 2012-04-26 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
WO2011056894A2 (en) 2009-11-03 2011-05-12 Jensen Michael C TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION
DK3012268T3 (en) 2010-09-08 2018-02-19 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Chimeric antigen receptors with an optimized hinge region
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
PL2718322T3 (pl) 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
ES2774160T3 (es) 2012-02-13 2020-07-17 Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos
SG11201404285VA (en) 2012-02-22 2014-10-30 Univ Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
AU2014376328A1 (en) 2014-01-13 2016-07-21 Christine E. BROWN Chimeric antigen receptors (CARs) having mutations in the Fc spacer region and methods for their use
IL308324A (en) 2014-09-19 2024-01-01 Hope City IL13RA2-targeted chimeric antigen receptor T cells

Also Published As

Publication number Publication date
RU2711114C2 (ru) 2020-01-15
JP7160882B2 (ja) 2022-10-25
KR20220098048A (ko) 2022-07-08
KR102297918B1 (ko) 2021-09-03
KR102416258B1 (ko) 2022-07-05
DK2968415T3 (da) 2019-10-21
MX2015013195A (es) 2016-04-15
WO2014144622A2 (en) 2014-09-18
EP2968415B1 (en) 2019-07-31
CN105392887A (zh) 2016-03-09
CA2907216C (en) 2024-02-27
JP6793800B2 (ja) 2020-12-02
EP3626247B1 (en) 2023-07-12
JP2021036886A (ja) 2021-03-11
KR102556831B1 (ko) 2023-07-19
MX2020001358A (es) 2020-08-20
EP2968415A2 (en) 2016-01-20
IL289883A (en) 2022-03-01
JP2020010699A (ja) 2020-01-23
CA2907216A1 (en) 2014-09-18
IL281562B (en) 2022-02-01
US11918606B2 (en) 2024-03-05
US10660916B2 (en) 2020-05-26
AU2014228911A1 (en) 2015-10-08
KR20210111879A (ko) 2021-09-13
KR102506668B1 (ko) 2023-03-07
US9657105B2 (en) 2017-05-23
JP2016514457A (ja) 2016-05-23
IL289883B (en) 2022-12-01
NZ712351A (en) 2021-07-30
ES2747099T3 (es) 2020-03-10
JP6588004B2 (ja) 2019-10-09
IL281562A (en) 2021-05-31
US20200254023A1 (en) 2020-08-13
IL289883B2 (en) 2023-04-01
BR112015023701B1 (pt) 2022-01-11
WO2014144622A3 (en) 2015-06-11
US20140271582A1 (en) 2014-09-18
KR20160012991A (ko) 2016-02-03
CN111926028A (zh) 2020-11-13
EP2968415A4 (en) 2017-01-04
IL241668B (en) 2021-04-29
KR20230035704A (ko) 2023-03-14
IL298332A (en) 2023-01-01
AU2021202705A1 (en) 2021-05-27
EP3626247A1 (en) 2020-03-25
BR112015023701A2 (pt) 2017-07-18
JP2022191388A (ja) 2022-12-27
CN105392887B (zh) 2020-05-29
RU2015140624A (ru) 2017-04-26
BR112015023701A8 (pt) 2020-03-10
US20170260277A1 (en) 2017-09-14
AU2019202394A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
HK1222677A1 (zh) 特異性嵌合抗原受體重導向性 細胞及其使用方法
HK1253407A1 (zh) 嵌合抗原受體及其使用方法
HK1258274A1 (zh) 抗體/t細胞受體嵌合構建體及其用途
HK1222679A1 (zh) 特異性嵌合抗原受體及其用途
IL261941A (en) Chimeric antigen and t cell receptors and methods of use
HK1224332A1 (zh) 人類間皮素嵌合性抗原受體及其用途
HK1222186A1 (zh) 嵌合抗原受體
IL254068A0 (en) Anti-dll3 chimeric antigen receptors and methods of use
HK1220206A1 (zh) 抗體及其用途
HK1256130A1 (zh) 用於嵌合抗原受體和其他受體的表達的t細胞
HK1222674A1 (zh) 工程化嵌合抗原受體 細胞的人應用
IL237576A0 (en) Multi-chain chimeric antigen receptor and uses thereof
DK3192812T3 (da) Anti-CD3-antistoffer og fremgangsmåder til anvendelse
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
HK1205144A1 (zh) 雙特異性嵌合抗原受體及其治療用途
DK2970460T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
DK3026062T3 (da) Anti-pd-1-antistof og anvendelse deraf
DK2992020T3 (da) Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller
DK3086807T3 (da) Antistoffer og fremgangsmåder til anvendelse
HK1218421A1 (zh) 抗胰高血糖素受體抗體和其使用方法
EP2947906A4 (en) METHOD AND CHARGING DEVICE
LT3068800T (lt) Fcrn receptoriui specifiniai antikūnai